Monograph
Galleri — The Multi-Cancer Early Detection Blood Test, and What the 2026 Data Actually Shows
The NHS-Galleri trial missed its primary endpoint at ASCO 2026. High specificity (~99.6%) and PPV (52-62%), modest sensitivity (~30-40% all cancers), zero mortality data. $949 cash pay. No FDA approval as screening. Vanguard's read on the largest multi-cancer detection trial to date.
By Kristopher Crawford
·
19 July 2026
·
5 min read
The NHS-Galleri trial missed its primary endpoint at ASCO 2026. High specificity (~99.6%) and PPV (52-62%), modest sensitivity (~30-40% all cancers), zero mortality data. $949 cash pay. No FDA approval as screening. Vanguard's read on the largest multi-cancer detection trial to date.
MEMBERS ONLY
Continue Reading
This article is available to Vanguard members. Join to access all physician-curated content.
